UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) announced plans to expand beyond its core neurology focus to evaluate the acquisition of complementary anti-aging technologies. The company aims to develop treatments targeting healthy brain function, organ health, and longevity indicators.

Building on its existing programs KLTO-101 and KLTO-202 for neurodegenerative diseases, Klotho is exploring treatments related to the Klotho gene, which is linked to aging and longevity. The company's expanded focus includes targeting conditions such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia, and osteoporosis.

The initiative involves assembling a scientific team to evaluate genes and proteins including alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin, with the goal of developing interventions to delay age-related diseases.

Positive

• Strategic expansion beyond neurology into broader longevity and anti-aging markets
• Development progress of two lead compounds KLTO-101 and KLTO-202
• Potential to address multiple age-related diseases through Klotho gene targeting

Negative

• Early-stage expansion with no immediate revenue potential
• Increased operational complexity from broader development focus
• Additional capital likely needed to fund multiple development programs

Insights

Biotech Investment Strategist

Klotho's expansion beyond neurology into broader longevity markets represents a strategic pivot that diversifies their pipeline but lacks specific implementation details.

Klotho Neurosciences is strategically expanding beyond its core neurodegenerative focus into broader longevity and anti-aging applications—a significant pivot that could substantially expand their addressable market. While they've begun manufacturing KLTO-101 and KLTO-202 (presumably their lead neurology candidates), they're now evaluating acquisitions in complementary longevity technologies.

This announcement signals a major strategic expansion but remains notably light on specifics. The company mentions no concrete acquisition targets, timelines, investment amounts, or development roadmaps for these new initiatives. They identify promising biomolecular targets beyond Klotho (including FOXO3 and anti-myostatin pathways), but provide no details on their approach to these targets or how far along any development might be.

The scientific rationale appears sound—Klotho's role as a "master gene" affecting multiple aging pathways gives credibility to this expansion. However, the lack of specificity raises questions about implementation. Are they early in the evaluation process, or holding details close for competitive reasons? The press release reads more like a statement of general direction rather than a concrete business development announcement.

This expansion potentially transforms Klotho from a neurology-focused player into a broader longevity platform company, which could significantly alter their competitive positioning and market opportunity. However, without more concrete details on implementation timeline, capital requirements, or specific programs, investors have little to evaluate regarding near-term impact.

Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators

NEW YORK, July 25, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.

In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life.

"As announced previously, we've begun manufacturing and development of KLTO-101 and KLTO-202," said Klotho CEO Dr. Joseph Sinkule. "We're also exploring other treatments that could support healthy aging and extend human longevity."

The human Klotho gene is strongly linked to aging and longevity. Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration.

"The Klotho gene is what we call a master gene," stated Shalom Hirschman, M.D., world-renowned physician and senior consultant to the Company. "The Klotho gene has pleotropic actions modulating many critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways leading to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be prevented by two alpha-Klotho protein isoforms – soluble Klotho and secreted-Klotho."

"We're assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators," said Jeffrey LeBlanc, Klotho CFO. "This includes evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms."

Dr. Sinkule added, "If people don't die of cancer or trauma, they often succumb to age-related diseases of the brain, heart, kidneys, liver, bone, or muscle. Our mission is to identify and develop complementary assets to delay these outcomes through targeted research and intervention."

About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO, ir@klothoneuro.com

Website: www.klothoneuro.com.

Forward-Looking Statements:

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements.  All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/updated-klotho-neurosciences-inc-to-expand-development-programs-beyond-neurology-302514323.html

SOURCE Klotho Neurosciences, Inc.

FAQ

What is Klotho Neurosciences (KLTO) new business expansion strategy?

KLTO is expanding beyond neurology to evaluate complementary technologies targeting brain function, muscle strength, bone health, and longevity indicators, focusing on the Klotho gene's role in aging and age-related diseases.

What are the main products in KLTO's development pipeline?

KLTO's main products currently in development are KLTO-101 and KLTO-202, which target brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's.

What diseases does Klotho Neurosciences plan to target with its expanded focus?

KLTO plans to target multiple age-related conditions including cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue.

What is the significance of the Klotho gene in KLTO's research?

The Klotho gene is considered a 'master gene' that modulates critical cellular pathways affecting aging and longevity, including insulin resistance, growth factors, and cell-damaging mechanisms that can be prevented by Klotho protein isoforms.

Which specific proteins and genes is KLTO evaluating for its longevity research?

KLTO is evaluating several key proteins and genes including alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms for their potential in targeting age-related diseases.